Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 6/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546620 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13403392 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3553836 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13403388 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3331405 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3546617 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1336035 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8858635 | 1.00 | CTSC (0.45) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL1493678 | 0.98 | CTSC (0.44) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL13570570 | 0.98 | CTSC (0.44) | CTSCCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138486-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024051721-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4301363-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | Nikang Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117255684-A | Quinazolinamine derivatives as KRAS inhibitors | 尼坎治疗公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116867792-A | Tetraepoxyazepine compound and use thereof | 基因泰克公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187528-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022187527-A1 | QUINAZOLINE NITRILE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-3074384-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-5605877-A | TETRAHYDROPYRROLO(1,2-C)IMIDAZOLE-1,3-DIONES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0659187-A1 | BICYCLIC IMIDES AS HERBICIDES | DEGUSSA AG (DE) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005668-A1 | BICYCLIC IMIDES AS HERBICIDES | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | CTSC 2064/4885CHRNB2 987/4885CHRNA4 392/4885 |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | CTSC 2487/4885CHRNB2 4384/4885CHRNA4 4595/4885 |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | CTSC 751/4885CHRNB2 613/4885CHRNA4 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.